Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group. Shapiro J, et al. Among authors: van der sangen mjc, van dekken h, van rij cm, van laarhoven hwm, van berge henegouwen mi, van der gaast a, van hagen p, van lanschot jjb. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5. Lancet Oncol. 2015. PMID: 26254683 Clinical Trial.
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ. van Heijl M, et al. Among authors: van lanschot jj, van dekken h, van berge henegouwen mi, van der gaast a. Ann Surg. 2011 Jan;253(1):56-63. doi: 10.1097/SLA.0b013e3181f66596. Ann Surg. 2011. PMID: 21233607 Clinical Trial.
Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial.
Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, Siersema PD, Dinjens WN, van Lanschot JJ, Tilanus HW, van der Gaast A. Boonstra JJ, et al. Among authors: van lanschot jj, van heijl m, van berge henegouwen mi, van der gaast a. BMC Cancer. 2011 May 19;11:181. doi: 10.1186/1471-2407-11-181. BMC Cancer. 2011. PMID: 21595951 Free PMC article. Clinical Trial.
Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.
Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, van der Sangen MJ, Beukema JC, Rütten H, Spruit PH, Reinders JG, Richel DJ, van Berge Henegouwen MI, Hulshof MC. Oppedijk V, et al. Among authors: van os r, van lanschot jj, van rij cm, van der gaast a, van berge henegouwen mi, van hagen p, van der sangen mj. J Clin Oncol. 2014 Feb 10;32(5):385-91. doi: 10.1200/JCO.2013.51.2186. Epub 2014 Jan 13. J Clin Oncol. 2014. PMID: 24419108 Clinical Trial.
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.
Koen Talsma A, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, van Berge Henegouwen MI, Wijnhoven BP, van Lanschot JJ; CROSS Study Group; Hulshof MC, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW. Koen Talsma A, et al. Among authors: van lanschot jj, van dekken h, van laarhoven hw, van rij cm, van der gaast a, van berge henegouwen mi, van hagen p, van der sangen mj. Ann Surg. 2014 Nov;260(5):786-92; discussion 792-3. doi: 10.1097/SLA.0000000000000965. Ann Surg. 2014. PMID: 25379850 Clinical Trial.
Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.
Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group. Shapiro J, et al. Among authors: van lanschot jj, van der gaast a, van hagen p. Ann Surg. 2014 Nov;260(5):807-13; discussion 813-4. doi: 10.1097/SLA.0000000000000966. Ann Surg. 2014. PMID: 25379852 Clinical Trial.
Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer.
Nederlof N, Slaman AE, van Hagen P, van der Gaast A, Slankamenac K, Gisbertz SS, van Lanschot JJ, Wijnhoven BP, van Berge Henegouwen MI; CROSS-Study Group. Nederlof N, et al. Among authors: van lanschot jj, van der gaast a, van berge henegouwen mi, van hagen p. Ann Surg Oncol. 2016 Nov;23(12):3964-3971. doi: 10.1245/s10434-016-5291-3. Epub 2016 Jun 14. Ann Surg Oncol. 2016. PMID: 27301849 Free PMC article.
135 results